
Bharat Biotech’s COVID-19 vaccine candidate has shown an interim efficacy of 81% in a Phase III trial, the company announced …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

